Neurosciences Victoria Ltd
Overview
Neurosciences Victoria offers facilitated access into the Australian neuroscience industry, providing management, scientific and commercial expertise and experience in developing multi-national and multi-centre collaborative research partnerships.
NSV is an excellent gateway to Australia’s world-class scientists and the best of its research institutes, universities and facilities. It offers access to a pan-Australian network of neuroscience infrastructure, technology and services and an experienced, commercially focused management team.
Create
- Discovery Science
- Research Infrastructure
- Pre-Clinical & Clinical Integration
Collaborate
- Multi-Centre Research & Development Projects
- Multi-Centre Pre-Clinical Development Facilities
- Science-Industry Partnerships
Commercialise
- Commerically Focused Project Portfolio
- Product Co-Development Opportunities
- Unified IP Management Policy
- Unitary Point of Contact for Negotiation
NSV Members
- 2 World Class Universities
- 7 Research Institutes
- 5 Major Teaching Hospitals
- 600+ Neuroscientists
NSV Industry Partners
- Schering AG (Germany)
- Berlex Biosciences (USA)
- Sojitz Corporation (Japan)
- Nhwa Pharmaceutical Corp (China)
- Prana Biotechnology (Australia)
- Starfish Ventures (Australia)
Number of employees
5
Specific focus of company
Core Business Definition
Neurosciences Victoria offers facilitated access into the Australian neuroscience industry, providing management, scientific and commercial expertise and experience in developing multi-national and multi-centre collaborative research partnership
Competitive advantages
Therapeutic Areas
- Neurodegeneration (Alzheimer’s disease, Parkinson’s disease, Motor Neuron disease)
- Stroke
- Epilepsy
- Pain (neuropathic, visceral, trigeminal)
- Multiple Sclerosis
- Neuropsychiatry (Schizophrenia, Addiction, Anxiety, Bipolar disorder, Depression)
- Addiction & Obesity
Pan Australian Discovery & Development Services
(available through Australia’s National Neuroscience Facility)
- Neurogenomics & Neuroproteomics
- National Neural Tissue Resource Centre
- Cellular Neurophysiology
- Neuroscience Informatics
- Neuroimaging
- Integrative Neuroscience Facility
- Clinical Neurobiology of Psychiatry
- Neuroscience Trials Australia
Opportunities
- NCE Licensing
- Co-development
- Drug validation & testing
- Drug discovery & development technologies
- Collaborative R & D
- Animal phenotyping
- Spin-off equity participation
- Clinical Trials
Main business focus/
Listing by sector:
- Research Organisation
Competitive Advantages
Therapeutic Areas
- Neurodegeneration (Alzheimer’s disease, Parkinson’s disease, Motor Neuron disease)
- Stroke
- Epilepsy
- Pain (neuropathic, visceral, trigeminal)
- Multiple Sclerosis
- Neuropsychiatry (Schizophrenia, Addiction, Anxiety, Bipolar disorder, Depression)
- Addiction & Obesity
Pan Australian Discovery & Development Services
(available through Australia’s National Neuroscience Facility)
- Neurogenomics & Neuroproteomics
- National Neural Tissue Resource Centre
- Cellular Neurophysiology
- Neuroscience Informatics
- Neuroimaging
- Integrative Neuroscience Facility
- Clinical Neurobiology of Psychiatry
- Neuroscience Trials Australia
Opportunities
- NCE Licensing
- Co-development
- Drug validation & testing
- Drug discovery & development technologies
- Collaborative R & D
- Animal phenotyping
- Spin-off equity participation
- Clinical Trials
Contact Details
| Contact person | Dr Andrew Milner |
|---|---|
| Job Title | Chief Executive Officer |
| Address | National Neuroscience Facility |
| Level 2, 161 Barry St | |
| City/Suburb | Carlton South |
| State | Victoria |
| info@neurosciencesvic.com.au | |
| Phone | +61 3 8344 1802 |
| Fax | +61 3 9348 1764 |
| Website | http://www.neurosciencesvic.com.au |
